|Bid||68.88 x 3200|
|Ask||0.00 x 800|
|Day's Range||68.05 - 69.77|
|52 Week Range||66.34 - 107.26|
|Beta (5Y Monthly)||0.60|
|PE Ratio (TTM)||22.88|
|Earnings Date||Aug 01, 2023 - Aug 07, 2023|
|Forward Dividend & Yield||2.42 (3.51%)|
|Ex-Dividend Date||Apr 20, 2023|
|1y Target Est||98.18|
Subscribe to Yahoo Finance Plus to view Fair Value for CVSLearn more
Adding these well-respected dividend payers to your portfolio could give you a stream of passive income that grows throughout your retirement years.
Oak Street Health said it's expanding into four new states this summer: Arkansas, Iowa, Kansas and Virginia. The Chicago-based provider of primary care for adults on Medicare said it will open new facilities in Little Rock, Arkansas; Des Moines and Davenport, Iowa; Kansas City, Kansas; and Richmond, Virginia, this summer. With these sites, Oak Street Health said it will operate in half of the states in the U.S. The company also said it plans to open new locations this year in states where it already operates, including Arizona, Colorado, Georgia, Illinois, Indiana, Louisiana, New York, Ohio and Pennsylvania.
Key Insights Significantly high institutional ownership implies CVS Health's stock price is sensitive to their trading...
The healthcare industry is diverse and complex, with longtime staples and emerging disruptors to fit your portfolio -- and it also doesn't need to cost an arm and a leg. Here are several possibilities to consider, each playing a different role in the healthcare system. In an industry where size matters, Pfizer (NYSE: PFE) is one of the industry's most prominent players, with a market cap of over $200 billion.
Investors are optimistic about CVS Health (CVS) on continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services.
While the concept of heavily bidding up blue-chip stocks for a healthy portfolio isn’t exactly the most exciting proposition, under the present circumstances, it could be the most sensible. Fundamentally, with Democrats and Republicans at loggerheads over the debt ceiling crisis, anything can happen. At the moment, Reuters reports that the two sides have made progress. Unfortunately, a deal remains in doubt. Naturally, the biggest concern centers on the U.S. defaulting on its obligations. Such a
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
The companies and their rivals say their enormous size and scope makes them the best candidates to fix America’s health care system. After a new wave of mergers, they're under pressure to prove it.
Alphabet, Raytheon, Blackstone, SAP SE and CVS Health are included in this Analyst Blog.
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Raytheon Technologies Corporation (RTX) and Blackstone Inc. (BX).
On Sunday, CVS Health (NYSE: CVS) revealed that it would be shuttering its clinical trial services segment by the end of 2024, according to reporting from biopharma industry trade publication Endpoints News. The pharmacy and health insurance giant began its foray into this space in 2021, and originally used its access to consumers to aid drugmakers in recruiting participants for COVID-19 vaccine trials and other coronavirus-related clinical investigations, but apparently, management doesn't feel that the business is contributing significantly to the company's prospects. Does this mean that CVS stock isn't as safe as shareholders have believed?
When CVS Health (NYSE: CVS) said on May 14 that it would exit its clinical trial services business after just two years in operation, management at Walgreens Boots Alliance (NASDAQ: WBA) was quick to confirm that it would still be moving forward full speed with building out its own service. Now, the smaller pharmacy chain will have the benefit of one less major competitor trying to work with drug developers to build out their clinical trials. Why bother to get into clinical trials in the first place?
Insiders have a longer-term holding horizon than most, a critical aspect that market participants should know. Nonetheless, seeing an insider step in and buy is always reassuring.
Laffer Tengler Investments CEO and CIO Nancy Tengler joins Yahoo Finance Live to discuss stocks to buy, including Starbucks, Chipotle, and Tesla, and stocks to avoid, including Disney and CVS.
In this article, we will take a look at billionaire Ray Dalio’s top 12 stock picks. You can skip our detailed analysis of Ray Dalio’s hedge fund and recent developments, and go directly to read Billionaire Ray Dalio’s Top 5 Dividend Stock Picks. Ray Dalio founded Bridgewater Associates in 1975. Today, it is one of […]
Aetna Better Health of Virginia, a CVS Health company (NYSE: CVS), and Virginia Community Healthcare Association (VCHA) announced that Aetna provided a total of $7.3 million in value-based care incentive payments to 22 Federally Qualified Health Centers, also known as Community Health Centers, in Virginia. The funds aim to help health centers improve quality of care by enabling their population health management programs and increasing screenings for diabetes as well as breast, cervical and colo
All of these stocks offer reliable dividend payments that could help make your retirement dreams a reality.
Walgreens remains bullish on its clinical trials segment as rival CVS announces closure.
CVS's clinical trials venture, launched during the pandemic, will reportedly close by the end of 2024.
Back in May of 2021, CVS Health launched the firm's clinical trial services business that was aimed at leveraging a collaborative effort with "big pharma" to support testing for experimental Covid-19 vaccines and therapeutics during the pandemic and beyond. CVS Health confirmed the story, stating, "We're winding down our Clinical Trial Services business in a phased way with a full exit expected by December 2024." CVS Health posted first quarter earnings.
It is hard to get excited after looking at CVS Health's (NYSE:CVS) recent performance, when its stock has declined 24...
Many of the greatest investors of all time could be considered value investors. One stock that seems to be greatly undervalued right now is pharmacy chain and health insurer CVS Health (NYSE: CVS). Let's take a peek under the hood at its fundamentals and valuation to better understand why the stock could be a no-brainer buy for value investors this month and beyond.
Independent pharmacies and startups such as Cigna's Express Scripts and Mark Cuban's Cost Plus Drugs are partnering up to address a coverage gap for some Americans.
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Walmart (NYSE: WMT) is a large, well-funded, low-cost competitor that no company wants to go up against if they can avoid it. For big pharmacy retailers such as Walgreens Boots Alliance (NASDAQ: WBA) and CVS Health (NYSE: CVS), may soon find out what it feels like (even more than they already do). Walmart is a dominant name in retail as its low-priced merchandise draws in many consumers looking to save money, particularly now amid outsized and persistent inflation.